
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Francisco - Designed to treat difficult cases of cutaneous T-cell lymphoma, photopheresis is proving to have several more potential clinical applications, including graft-versus-host disease (GVHD) and lichen planus.






